News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Stentys Revenues for the First 9 Months of 2012 up 88% over Prior Year


10/22/2012 12:16:39 PM

PRINCETON, N.J. & PARIS--(BUSINESS WIRE)--STENTYS (FR0010949404 – STNT), a medical technology company commercializing in Europe the world's first and only Self-Apposing® stent to treat acute myocardial infarction (AMI), today reports its third-quarter and 9-month revenues through 30 September 2012.

Read at BioSpace.com

comments powered by Disqus
Stentys
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES